[SP5-3C-1] Prognostic Indicators and Effectiveness of Treatments for Acute Encephalopathy with Biphasic Seizures and Late Reduced Diffusion
[Introduction] Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most frequent subtype of acute encephalopathy during childhood in Japan. Although the patients often have severe neurological sequelae, the prognostic indicators and treatment strategy have not been established. The present study aimed to disclose the determinants of neurological outcome and the effectiveness of treatments for AESD.
[Methods] We enrolled a total of 20 AESD patients who were diagnosed in our department and followed up over 1 year. We retrospectively reviewed the demographics, clinical symptoms, laboratory data, quantitatively assessed MRI findings and specific treatments, and compared them between patients who had ‘severe’ and ‘non-severe’ prognoses.
[Results] Severe patients showed coma and involuntary movements and more extensive lesions in the cerebrum and basal ganglia in MRI. A variety of treatments were combined including steroid pulse therapy, intravenous immunoglobulin and therapeutic hypothermia for both the groups. These treatments seemed not to change the neurological prognoses although the timing of the treatment initiation was ranged widely.
[Conclusions] The majority of our patients suffered from neurological sequelae even with the combined therapies. Further studies are required to disclose how and when to treat AESD.
[Methods] We enrolled a total of 20 AESD patients who were diagnosed in our department and followed up over 1 year. We retrospectively reviewed the demographics, clinical symptoms, laboratory data, quantitatively assessed MRI findings and specific treatments, and compared them between patients who had ‘severe’ and ‘non-severe’ prognoses.
[Results] Severe patients showed coma and involuntary movements and more extensive lesions in the cerebrum and basal ganglia in MRI. A variety of treatments were combined including steroid pulse therapy, intravenous immunoglobulin and therapeutic hypothermia for both the groups. These treatments seemed not to change the neurological prognoses although the timing of the treatment initiation was ranged widely.
[Conclusions] The majority of our patients suffered from neurological sequelae even with the combined therapies. Further studies are required to disclose how and when to treat AESD.